IMU 2.00% 5.1¢ imugene limited

Ann: First Cohort 2 Patient Dosed in Clinical Trial of CHECKvacc, page-3

  1. 3,238 Posts.
    lightbulb Created with Sketch. 7084
    Imugene MD & CEO Leslie Chong said “We are pleased with the results that we have seen so far in cohort 1 with no observed toxicity with early encouraging results in oncolytic virus infection and replication in the TNBC tumours. We look forward to continuing this study and reporting to the market of its progress.”

    As I keep saying. Get your information from Leslie Chong. Straight from the horses mouth.
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Last
5.1¢
Change
0.001(2.00%)
Mkt cap ! $371.1M
Open High Low Value Volume
5.1¢ 5.2¢ 5.0¢ $221.0K 4.337M

Buyers (Bids)

No. Vol. Price($)
83 5041219 5.0¢
 

Sellers (Offers)

Price($) Vol. No.
5.1¢ 541475 19
View Market Depth
Last trade - 12.35pm 07/08/2024 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.